Elsevier

Experimental Gerontology

Volume 60, December 2014, Pages 79-82
Experimental Gerontology

Short report
Serum levels of C-terminal agrin fragment (CAF) are associated with sarcopenia in older hip fractured patients

https://doi.org/10.1016/j.exger.2014.10.003Get rights and content

Abstract

Background

Serum concentrations of the C-terminal fragment of agrin (CAF), a component of the neuromuscular junction (NMJ), are elevated in older community-dwellers with sarcopenia. Whether CAF may be used as a marker for muscle wasting in the presence of NMJ mechanical damage is presently unknown. The present study was undertaken to verify if serum CAF levels were associated with sarcopenia in older hip fractured patients.

Methods

Analyses were conducted in older adults hospitalized for traumatic hip fracture. The presence of sarcopenia was established according to the European Working Group on Sarcopenia in Older People criteria, with bioelectrical impedance analysis used for muscle mass estimation. Serum levels of CAF were determined using a commercial ELISA kit.

Results

Among 42 hip fractured patients (age 83.7 ± 8.6 years, 76.2% women), sarcopenia was diagnosed in 7 individuals (16.7%). Serum CAF levels were significantly higher in sarcopenic relative to non-sarcopenic patients (172.2 ± 47.5 pM vs. 93.1 ± 44.0 pM; p < 0.001). The association remained significant in both genders after adjustment for several potential confounders.

Conclusion

Elevated serum CAF concentrations are associated with sarcopenia in older adults with hip fracture. The determination of serum CAF levels could therefore serve to identify a subset of hip fractured patients at especially high risk for adverse health outcomes.

Introduction

Hip fracture is the most burdensome consequence of osteoporosis. Approximately 1.6 million older adults sustain a hip fracture worldwide annually, and this figure is projected to worsen due to the ongoing demographic transition (Pioli et al., 2014). Although advancements have been made in the surgical and clinical management of hip fractured patients, mortality rates remain extremely high (over 30% at one year), with incomplete restoration of pre-fractural conditions in more than 50% of survivors (Maggi et al., 2010). These considerations call for the development of novel strategies to improve the survival and functional recovery of this vulnerable patient population.

Among the factors that may impact the clinical outcome of hip fractured elderly, the age-related loss of muscle mass and function (sarcopenia) emerges as serious candidate for interventions. Indeed, the skeletal muscle, besides its role in mobility, is also critically involved in inflammatory and immune signaling, glucose disposal, and protein synthesis. Notably, the presence of sarcopenia was identified as an independent predictor of poor clinical outcomes, including disability and mortality, in older adults admitted to acute care (Vetrano et al., 2014) or intensive care units (ICUs) (Moisey et al., 2013).

The limited availability of equipment for muscle mass estimation and difficulties with functional testing in critically ill patients have so far impeded the incorporation of sarcopenia into standard practice. Considerable research efforts have therefore been diverted toward developing and validating blood-borne biomarkers for sarcopenia which could obviate the need for imaging and performance testing (Marzetti, 2012).

The circulating C-terminal agrin fragment (CAF) has recently been proposed as a marker for muscle atrophy in both humans (Drey et al., 2013, Hettwer et al., 2013) and animal models (Bütikofer et al., 2011). Agrin is a heparan sulfate proteoglycan synthesized in motor neurons, transported along axons and released into the synaptic basal lamina of the neuromuscular junction (NMJ), where it induces the assembly of the postsynaptic apparatus, including the clustering of acetylcholine receptors, and the stabilization of presynaptic structures (Stephan et al., 2008). The proteolytic cleavage of agrin at the NMJ by neurotrypsin produces a C-terminal 22-kDa fragment (CAF), which is released into the circulation and is therefore measurable (Stephan et al., 2008). In mice, overexpression of neurotrypsin in motor neurons results in reduced agrin levels at the NMJ (Bütikofer et al., 2011). These mice are characterized by early declines in muscle mass and strength, with histopathological traits mimicking those of sarcopenia (e.g., type II fiber loss, increased heterogeneity of fiber diameter, higher frequency of centralized nuclei, fiber-type grouping, and type I to type II fiber transition) (Bütikofer et al., 2011). These findings indicate that an excessive cleavage of agrin results in NMJ fragmentation and fiber denervation, which in turn may contribute to the pathogenesis of sarcopenia.

While studies have shown that serum CAF may serve as a biomarker for sarcopenia in community-dwelling elderly (Drey et al., 2013, Hettwer et al., 2013), its validity in the presence of acute medical conditions has yet to be established. In particular, in traumatized patients, such as those sustaining a hip fracture, the muscular mechanical damage could result in extensive shedding of NMJ constituents, including CAF, into the circulation. This could theoretically offset eventual pre-existing differences linked to the presence of sarcopenia, thereby precluding the use of CAF as a muscle wasting biomarker in this patient population.

Based on these considerations, the present exploratory study was undertaken to verify if serum CAF levels were associated with sarcopenia in a cohort of older adults hospitalized for traumatic hip fracture.

Section snippets

Study sample

The study was performed between November 2012 and August 2013 among older adults admitted for hip fracture due to accidental fall to the Emergency Department (ED) of the Teaching Hospital “Agostino Gemelli”, Catholic University of the Sacred Heart (Rome, Italy). Exclusion criteria were age < 65 years, presence of peripheral edema, bone metastasis, cognitive impairment (Cognitive Performance Scale, CPS < 3), presence of pacemaker or implantable cardioverter defibrillator, and unwillingness to take

Results

A total of 42 hip fractured patients were enrolled for the study. The main characteristics of the study sample are shown in Table 1. Women were predominant (76.2%), which is coherent with epidemiological data showing a higher incidence of hip fracture in the female gender (Cauley et al., 2014). Sarcopenia was identified in 7 patients (16.7%), with a higher prevalence in men than women. Relative to non-sarcopenic patients, subjects with sarcopenia showed poorer pre-fractural physical function,

Discussion

Over the last decades, considerable efforts have been directed toward the development of interventions aimed at reducing the incidence of hip fractures and improving the health outcomes once the fracture has occurred (Pioli et al., 2014). Yet, the prognosis of older adults with hip fractured remains extremely poor (Maggi et al., 2010). Indeed, a shift of paradigm is necessary to optimize the management of such a vulnerable patient population. Accordingly, hip fracture should no longer be viewed

Conflict of interest

None of the authors has any conflict of interest to disclose.

Acknowledgments

This study was supported by the “Centro Studi Achille e Linda Lorenzon” (E.M., L.M., R.C.), a grant from the Italian Ministry of Education, Universities and Research (MIUR — linea D3.2 2013; A.M.M., E.M., F.L.), and the Innovative Medicines Initiative Joint Undertaking (IMI-JU 115621; E.M., F.L., R.C.).

References (20)

There are more references available in the full text version of this article.

Cited by (54)

  • Biomarkers shared by frailty and sarcopenia in older adults: A systematic review and meta-analysis

    2022, Ageing Research Reviews
    Citation Excerpt :

    The pathophysiology of frailty and sarcopenia resembles that of other prototypical geriatric conditions, for which a multifactorial etiology is at play involving many of the biological hallmarks of aging (i.e., genomic and epigenetic instability, loss of proteostasis, mitochondrial dysfunction, telomere shortening, dysregulated nutrient signaling, stem cell exhaustion, cellular senescence, and altered intercellular signaling) (Justice et al., 2018; López-Otín et al., 2013; Sierra, 2016). Currently available biomarkers of biological aging might not capture the multitude of intrinsic and extrinsic factors underlying the decline in physical function that characterizes frailty and sarcopenia (El Assar et al., 2021; Marzetti et al., 2014a, 2014b; Rodríguez-Mañas et al., 2021). However, perturbations in the above-mentioned aging pillars have been proposed as an important contributors to frailty and sarcopenia (Sierra, 2016).

  • Molecular mechanisms of exercise providing therapeutic rationale to counter sarcopenia

    2021, Sarcopenia: Molecular Mechanism and Treatment Strategies
View all citing articles on Scopus
1

These two authors contributed equally to this work.

View full text